Printer Friendly

Caradigm Adds Insignia Health's Patient Activation Measure Survey into Its Care Management Solution.

M2 PHARMA-August 3, 2017-Caradigm Adds Insignia Health's Patient Activation Measure Survey into Its Care Management Solution


- US-based GE Healthcare's Caradigm enterprise population health business has integrated Insignia Health's Patient Activation Measure (PAM) self-management survey into Caradigm's Care Management solution to help large integrated delivery networks, academic medical centres, government facilities and community hospitals gain better results in clinical outcomes while reducing costs, the company said.

PAM measures the ability of individuals to self-manage their health and healthcare by segmenting respondents into one of four activation levels along a 100-point scale.

These results provide insight into behaviours, characteristics, attitudes and motivators for health self-management, and can be used as a key indicator in clinical practice and health coaching.

PAM is supported by over a decade of health research and more than 350 peer-reviewed published studies.

In 2016, PAM was endorsed by the National Quality Forum as a person and family-centered care measure.

State Medicaid programs in a number of states mandate use of PAM, including New York and Washington, and PAM is accepted as a MIPS measure for Medicare reimbursement under MACRA.

According to the company, research consistently shows that as activation increases, patients become more adherent to medication and treatment plans, less likely to utilize expensive emergency and hospital services, and more satisfied with the care they receive.

The predictive power of PAM helps healthcare professionals better allocate their time and resources.

Caradigm, a GE Healthcare company, is a population health company dedicated to improving patient care, advancing the health of populations and reducing healthcare costs.

Its enterprise software portfolio encompasses all capabilities critical to delivering effective population health management, including data control; healthcare analytics; and care coordination and engagement.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 3, 2017
Previous Article:Symbiotix Biotherapies Names Mikhail as Executive Chairman of Its Board of Directors.
Next Article:Virta Health Names Former CMS Head Berwick Joins Board of Directors.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters